Skip to main content

Table 1 Patient characteristics

From: Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists

  Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
Age, [median (IQR)] 78.0 (70–84) 77.0 (69–82) 79.0 (72–84) 0.064
Gender (male) 199 (57.5) 45 (60.8) 154 (56.6) 0.518
Comorbidities
 Hypertension 146 (42.2) 30 (40.5) 116 (42.6) 0.745
 Diabetes 63 (18.2) 10 (13.5) 53 (19.5) 0.238
 Peripheral arterial disease 26 (7.5) 6 (8.1) 20 (7.4) 0.827
 Hypertensive cardiopathy 75 (21.7) 17 (23.0) 58 (21.3) 0.760
 Coronary heart disease 91 (26.3) 14 (18.9) 77 (28.3) 0.104
 Valvular cardiopathy 75 (21.7) 15 (20.3) 60 (22.1) 0.741
 Chronic kidney disease 99 (28.6) 25 (33.8) 74 (27.2) 0.267
 Liver insufficiency 6 (1.7) 2 (2.7) 4 (1.5) 0.472
 COPD 21 (6.1) 6 (8.1) 15 (5.5) 0.407
 Venous thromboembolism 61 (17.6) 11 (14.9) 50 (18.4) 0.481
 Aortic disease 15 (4.3) 3 (4.1) 12 (4.4) 0.893
 Stroke 48 (13.9) 9 (12.2) 39 (14.3) 0.631
 Carcinoma 37 (10.7) 16 (21.6) 21 (7.7) 0.001
 Coagulopathy 13 (3.8) 1 (1.4) 12 (4.4) 0.220
  1. Abbreviation: DOAC direct oral anticoagulants, COPD chronic obstructive pulmonary disease